Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
McKinsey
Argus Health
Daiichi Sankyo
Novartis
Deloitte
Dow
Queensland Health
Moodys

Generated: February 23, 2018

DrugPatentWatch Database Preview

DEPAKOTE ER Drug Profile

« Back to Dashboard

When do Depakote Er patents expire, and when can generic versions of Depakote Er launch?

Depakote Er is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-seven countries.

The generic ingredient in DEPAKOTE ER is divalproex sodium. There are seventeen drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

US Patents and Regulatory Information for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DEPAKOTE ER
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2/8/2005
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 5/3/2004

International Patents for DEPAKOTE ER

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Accenture
Mallinckrodt
Chinese Patent Office
Merck
Farmers Insurance
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot